COMPANY RESEARCH 06
Samsung Biologics’ Peptide Expansion
Acquisition Economics and Capital Efficiency
Key Conclusion
Acquiring PolyPeptide offers Samsung Biologics a credible route to peptide processes, customer programmes and overseas manufacturing sites. Target revenue growth and improved reported EBITDA do not guarantee immediate margin accretion or adequate returns for the buyer’s shareholders. Recurring earnings and cash generation must recover both the purchase consideration and subsequent capital and working-capital investment.
Research Summary
Samsung Biologics plans to expand its antibody-led CDMO platform through the acquisition of PolyPeptide. The offer is CHF 44.31 per share, implying approximately CHF 1.46bn of equity value. A roughly KRW 3tn rights offering is planned to fund the acquisition and Bio Campus II. The analysis date, 10 October 2026, precedes the scheduled end of the main offer period on 12 October. Acceptance, regulatory approval, closing and consolidation remain distinct milestones.
PolyPeptide’s first-half revenue grew 41.6%, and the company reported an EBITDA margin of 20.7%. Calculating from underlying figures gives 20.75%; removing only EUR 9.2m of intangible-asset disposal income gives a 16.86% reference margin, not company-adjusted EBITDA or a normalised forecast. Company-defined free cash flow turned from a EUR 0.516m inflow a year earlier to a EUR 19.102m outflow. Commercial and development revenue, one-off income, capitalised capex, cash asset purchases and working-capital balances require separate assessment.
TradeLens views the portfolio direction positively without transferring the existing antibody margin to the target. Weighted margins and reverse earnings requirements are illustrations, not consolidated forecasts or actual ROIC. Target guidance also excludes potential costs and expenses of the Samsung Biologics transaction. Acquisition performance should be tested through recurring earnings and incremental cash after commercial output, collections, reinvestment and working capital stabilise. Closing the transaction and adding revenue do not themselves establish capital recovery.
Key Points
- Tender acceptance, regulatory approval and closing are separate milestones. Offered equity value is not enterprise value or an immediate operating expense.
- The reported 20.7% EBITDA margin recalculates to 20.75% from underlying figures; a disposal-only sensitivity gives 16.86%, not company-adjusted EBITDA.
- Company-defined FCF turned from a EUR 0.516m inflow to a EUR 19.102m outflow. Cash asset purchases, capitalised capex and customer advances are separate measures.
- Antibody and peptide capacity cannot be added in one unit. Process yield, purification, customer qualification and saleable output matter.
- Lower average margins can coexist with higher absolute profit. Acquisition success depends on recovering the consideration and subsequent capital and working-capital commitments.